Skip to main content
. 2024 Jan 19;16(2):305. doi: 10.3390/nu16020305

Figure 5.

Figure 5

Skeletal muscle strength and function in McPc-treated mice. (A) Grip strength and (B) rotarod latency in McPc-treated mice. McPc (100 mg/kg) was orally administered once a day for 7 days (n = 5). (C–F) Effect of McPc treatment on (C) grip strength, (D) rotarod latency, (E) gastrocnemius muscle weight, and (F) thickness in sciatic neurectomy (NTX) in mice (n = 5). McPc (75 mg/kg) was orally administered once a day for 28 days from 2 weeks after NTX. (G) The mRNA expression of Mstn, Fbxo32, and Trim63 in vehicle or McPc-treated NTX mice model. (H) Protein levels of muscle differentiation markers, MyoD, myogenin, and MyHC, in C2C12 myotubes incubated with McPc in a dose-dependent manner for 24 h. (I) Brightfield image by differentiation time of C2C12 myotubes treated with 100 μg/mL McPc in differentiation media (2% horse serum). (J) OXPHOS and (K) fatty-acid-oxidation-related gene expression in gastrocnemius muscle of vehicle or McPc-treated NTX mice. (L) Mitochondrial DNA content in gastrocnemius muscle of vehicle or McPc-treated NTX mice. The values represent the mean ± SEM; * p < 0.05, ** p < 0.01, and *** p < 0.001. ns = not significant. One-way ANOVA Tukey’s post hoc test was conducted for multiple comparisons and two-tailed unpaired Student’s t-test was conducted for single comparisons.